In light of the ongoing financial restructuring at Dendreon, PCRI reiterates its unequivocal support for their unique and life-prolonging therapy Provenge and we agree with the following statement that was developed collaboratively from all of the advocacy groups who were in attendance at the meeting, which includes NASPCC, PCRI, Men’s Health Network, Women Against Prostate Cancer, Cancer Research Institute, and Us TOO. 

“In support of patients' needs, we have historically been strong proponents of the development and availability of all new therapies for advanced prostate cancer patients. This includes PROVENGE® (sipuleucel-T) as the first and only FDA-approved immunotherapy for prostate cancer. We continue our support for the availability of this important treatment with confidence that it will remain available for patients based on our meeting and discussions with Dendreon. We collectively provide this statement as a part of our responsibilities to inform our patient communities during Dendreon’s corporate financial reorganization."